|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
self-injection
|
|
gptkbp:administeredOnceEvery
|
4 weeks
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
ankylosing spondylitis
|
|
gptkbp:ATCCode
|
L04AB06
|
|
gptkbp:blackBoxWarning
|
malignancy
serious infections
|
|
gptkbp:CASNumber
|
476181-74-5
|
|
gptkbp:contraindication
|
active serious infection
hypersensitivity to golimumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
|
|
gptkbp:drugClass
|
gptkb:biotechnology
immunosuppressant
|
|
gptkbp:form
|
intravenous solution
prefilled syringe
auto-injector
|
|
gptkbp:genericName
|
gptkb:golimumab
|
|
gptkbp:halfLife
|
about 14 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Simponi
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
TNF-alpha inhibitor
|
|
gptkbp:MedlinePlusID
|
a609032
|
|
gptkbp:monoclonalAntibodyType
|
human monoclonal antibody
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
25077438
DB06674
|
|
gptkbp:riskFactor
|
congestive heart failure exacerbation
hepatitis B reactivation
tuberculosis reactivation
|
|
gptkbp:routeOfAdministration
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:sideEffect
|
headache
hypertension
injection site reactions
upper respiratory tract infection
increased risk of infection
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:UNII
|
YJD7J8QF0N
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|